Atypical, invasive, recurring Crooke cell adenoma of the pituitary

Hormones

Volumn 11, Issue 1, 2012, Pages 94-100

  Rotondo, Fabio ^a   Cusimano, Michael ^a   Scheithauer, Bernd W ^b   Coire, Claire ^c   Horvath, Eva ^a   Kovacs, Kalman ^a  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b MAYO CLINIC   (United States)

^c Trillium Health Centre Missassauga   (Canada)

Author keywords

Crooke cell adenoma; Histology; Immunohistochemistry; Neoplasm; Ultrastructure

Indexed keywords

CABERGOLINE; TEMOZOLOMIDE;

ACTH SECRETING ADENOMA; ADULT; ARTICLE; ATAXIA; CANCER INVASION; CANCER SIZE; CASE REPORT; CUSHING DISEASE; ELECTRON MICROSCOPY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MUSCLE WEAKNESS; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PITUITARY CROOKE CELL ADENOMA; POSITRON EMISSION TOMOGRAPHY; RADIATION DOSE FRACTIONATION; STEREOTAXIC SURGERY; TRANSSPHENOIDAL HYPOPHYSECTOMY; TUMOR RECURRENCE; VISUAL FIELD DEFECT;

ADENOMA; ANTINEOPLASTIC AGENTS; DACARBAZINE; FEMALE; HUMANS; MIDDLE AGED; PITUITARY NEOPLASMS;

EID: 84859040583     PISSN: 11093099     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Kovacs K, Scheithauer BW, Horvath E, Lloyd RV, 1996 The World Health organization classification of adenohypophysial neoplasms. A proposed five-tier scheme. Cancer 78: 502-510.
2. Kovacs K, Horvath E 1986 Tumors of the pituitary gland. In: Hartmann WH, Sobin LH (eds) Atlas of tumor pathology, 2nd series, Fascicle 21. Armed Forces Institute of Pathology, Washington, DC.
3. Horvath E, Kovacs K, Killinger DW, Smyth HS, Platts ME, Singer W, 1980 Silent corticotropic adenomas of the human pituitary gland: a histologic, immunologic, and ultrastructural study. Am J Pathol 98: 617-638.
4. Horvath E, Kovacs K, Smyth HS, et al, 1988 A novel type of pituitary adenoma: morphological features and clinical correlations. J Clin Endocrinol Metab 66: 1111-1118.
5. Hassoun J, Charpin C, Jaquet P, Lissitzky JC, Grisoli F, Toga M, 1982 Corticolipotropin immunoreactivity in silent chromophobe adenomas: A light and electron microscopic study. Arch Pathol Lab Med 106: 25-30.
6. Ezzat S, Asa SL, Couldwell WT, et al, 2004 The prevalence of pituitary adenomas: a systematic review. Cancer 101: 613-619.
7. Asa SL, Ezzat S, 1998 The cytogenesis and pathogenesis of pituitary adenomas. Endocr Rev 19: 798-827.
8. Terada T, Kovacs K, Stefaneanu L, Horvath E, 1995 Incidence, pathology, and recurrence of pituitary adenomas: study of 647 unselected surgical cases. Endocr Pathol 6: 301-310.
9. Thapar K, Kovacs K, Scheithauer BW, et al, 1996 Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-1 antibody. Neurosurgery 38: 99-106.
10. Hsu DW, Hakim F, Biller BM, et al, 1993 Significance of proliferating cell nuclear antigen index in predicting pituitary adenoma recurrence. J Neurosurg 78: 753-761.
11. Minematsu T, Miyai S, Kajiya H, et al, 2005 Recent progress in studies of pituitary tumor pathogenesis. Endocrine 28: 37-41.
12. Levy A, 2004 Pituitary disease: presentation, diagnosis, and management. J Neurol Neurosurg Psychiatry 75: iii47-52.
13. Arafah BM, Nasrallah MP, 2001 Pituitary tumors: pathophysiology, clinical manifestations and management. Endocr Relat Cancer 8: 287-305.
14. Kovacs K, Hovath E, Kerenyi NA, Sheppard RH, 1976 Light and electron microscopic features of a pituitary adenoma in Nelson's syndrome. Am J Clin Pathol 65: 337-343.
15. Kovacs K, Horvath E, Coire C, et al, 2006 Pituitary corticotroph hyperplasia preceding adenoma in a patient with Nelson's syndrome. Clin Neuropathol 25: 74-80.
16. Scheithauer BW, Kovacs K, Horvath E, et al, 2008 Pituitary blastoma. Acta Neuropathol 116: 657-666.
17. Pernicone PJ, Scheithauer BW, Sebo TJ, et al, 1997 Pituitary carcinoma: a clinicopathologic study of 15 cases. Cancer 79: 804-812.
18. Zafar MS, Mellinger RC, Chason JL, 1984 Cushing's disease due to pituitary carcinoma. Henry Ford Hosp Med J 32: 61-65.
19. Holthouse DJ, Robbins PD, Kahler R, Knuckey N, Pullan P, 2001 Corticotroph pituitary carcinoma: case report and literature review. Endocr Pathol 12: 329-341.
20. Scheithauer BW, Jaap AJ, Horvath E, et al, 2002 Clinically silent corticotroph tumors of the pituitary gland. Neurosurgery 47: 723-729.
21. Kovacs K, Stefaneanu L, Ezzat S, Smyth HS, 1994 Prolactin-producing pituitary adenoma in a male-tofemale transsexual patient with protracted estrogen administration: a morphologic study. Arch Pathol Lab Med 118: 562-566.
22. Rotondo F, Kovacs K, Horvath E, Bell CD, Lloyd RV, Scheithauer BW, 2006 Immunohistochemical expression of nestin in the non-tumorous hypophysis and in pituitary neoplasms. Acta Neuropathol 111: 272-277.
23. Crooke AC, 1935 A change in the basophil cells of the pituitary gland common to conditions which exhibit the syndrome attributed to basophil adenoma. J Pathol Bacteriol 41: 339-349.
24. Felix UA, Horvath E, Kovacs K, 1981 Massive Crooke's hyalinization in corticotroph cell adenomas of the human pituitary: a histological, immunocytological and electron microscopic study of three cases. Acta Neurochir (Wien) 58: 235-243.
25. Neumann PE, Horoupian DS, Goldman JE, et al, 1984 Cytoplasmic filaments of Crooke's hyaline change belong to the cytokeratin class: an immunocytochemical and ultrastructural study. Am J Pathol 116: 214-222.
26. George DH, Scheithauer BW, Kovacs K, et al, 2003 Crooke's cell adenoma of the pituitary: an aggressive variant of corticotroph adenoma. Am J Surg Pathol 27: 1330-1336.
27. Horvath E, Kovacs K, Josse R, 1983 Pituitary corticotroph cell adenoma with marked abundance of microfilaments. Ultrastruct Pathol 5: 249-255.
28. Eschbacher JM, Coons SW, 2006 Cytokeratin CK20 is a sensitive marker for Crooke's cells and the early cytoskeletal changes associated with hypercortisolism within pituitary corticotrophs. Endocr Pathol 17: 365-376.
29. Horvath E, Scheithauer BW, Kovacs K, Lloyd RV 2002 Hypothalamus and pituitary. In: Graham DI, Lantos PL (Eds). Greenfield's Neuropathology Vol 1, New York, Arnold Publishers, NY; pp, 983-1062.
30. Ikeda H, Yoshimoto T, Ogawa Y, Mizoi K, Murakami O, 1997 Clinico-pathological study of Cushing's disease with large pituitary adenoma. Clin Endocrinol 46: 669-679.
31. Saeger W, Lüdecke DK, Geisler F 1990 The anterior lobe in Cushing's disease/syndrome. In Cushing's Syndrome, and Other Hypercortisolemic States. Progress on Endocrine Research and Surgery, vol 5, pp, 147-156. DK Lüdecke, G Chrousos, G Tolis (eds), New York: Raven Press.
32. Lüdecke DK, Flitsch J, Knappe UJ, Saeger W, 2001 Cushing's disease: a surgical view. J Neuro-Oncol 54: 151-166.
33. Thapar K, Scheithauer BE, Kovacs K, Pernicone PJ, Laws ER Jr, 1996 P-53 expression in pituitary adenomas and carcinomas. Correlation with invasiveness and tumor growth fractions. Neurosurgery 38: 765-770.
34. Scheithauer BW, Kovacs KT, Laws ER, Randall RV, 1986 Pathology of invasive pituitary tumors with special reference to functional classification. Neurosurgery 65: 733-744.
35. Gaffey TA, Scheithauer BW, Lloyd RV, et al, 2002 Corticotroph carcinoma of the pituitary: a clinicopathological study. J Neurosurg 96: 352-360.
36. Scheithauer BW, Gaffey TA, Lloyd RV, et al 2006 Pathobiology of pituitary adenomas and carcinomas. Neurosurgery 59: 341-53.
37. Kovacs K, Diep CC, Horvath E, et al, 2005 Prognostic indicators in an aggressive pituitary Crooke's cell adenoma. Can J Neurol Sci 32: 540-545.
38. Takeshita A, Inoshita N, Taguchi M, et al, 2009 High incidence of low O6-methylguanine DNA methyltransferase expression in invasive macroadenomas of Cushing's disease. Europ J Endocrinol 161: 553-559.
39. Grossman AB, 2005 Clinical review: diagnosis and management of pituitary carcinomas. J Clin Endocrinol Metab 90: 3089-3099.
40. Scheithauer BW, Kurtkaya-Yapicier O, Kovacs KT, Young WF Jr, Lloyd RV, 2005 Pituitary carcinoma: a clinicopathological review. Neurosurgery 56: 1066-1074.
41. Pernicone PJ, Scheithauer BW 1993 Invasive pituitary adenomas and pituitary carcinomas. In Lloyd RV (eds), Surgical pathology of the pituitary gland. Philadelphia, WB Sanders, Co, pp, 121-136.
42. Levine AJ, 1997 the cellular gatekeeper for growth and division. Cell 88: 323-331.
43. Lidhar R, Korbonits M, Jordan S, et al, 1999 Low expression of the cell cycle inhibitor p27Kip1 in normal corticotroph cells, corticotroph tumors, and malignant pituitary tumors. J Clin Endocrinol Metab 84: 3823-3830.
44. Vidal S, Kovacs K, Horvath E, et al, 2002 Topoisomerase II alpha expression in pituitary adenomas and carcinomas: relationship to tumor behavior. Mod Pathol 15: 1205-1212.
45. Lloyd RV, Jin L, Qian X, Kulig E, 1997 Aberrqant p27kip1 expression in endocrine and other tumors. Amer J Pathol 150: 401-407.
46. Serres MP, Zlotek-Klotkiewicz E, Concha C, et al, 2011 Cytoplasmic p27 is oncogenic and cooperates with Ras both in vivo and in vitro. Oncogene 30: 2846-2858.
47. Sumi T, Stefaneanu L, Kovacs K, Asa S, Rindi, 1993 Immunohistochemical study of p53 protein in human and animal pituitary tumors. Endocr Pathol 4: 95-99.
48. Kontogeorgos G, 2006 Predictive markers of pituitary adenoma behavior. Neuroendocrinology 83: 179-188.
49. Saeger W, 2004 Proliferation markers and cell cycle inhibitors in pituitary adenomas. Front Horm Res 32: 110-126.
50. Wolfsberger S, Wunderer J, Zachenhofer I, et al, 2004 Expression of cell proliferation markers in pituitary adenomas-correlation and clinical relevance of MIB-1 and anti-topoisomerase-II alpha. Acta Neurochir (Wien) 146: 831-839.